Digitalization project: Identification of cardiovascular risk patients and detection of advanced liver fibrosis in patients with type-2-diabetes using non-invasive scores in outpatient care in Hessen

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036758

Enrollment

200

Registered

2025-05-28

Start date

2025-10-10

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11 K76.0 K75.8 K74.0

Interventions

Group 1: This is a prospective, monocentric, non-interventional observational study (2025-2029) to investigate the prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) in pat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Unselected patients (age >=18 years) with diabetes mellitus type 2 from five diabetes specialist practices in Hessen. Informed consent for participation.

Exclusion criteria

Exclusion criteria: Known advanced liver disease (fibrosis =3, liver cirrhosis, HCC) in patients with diabetes mellitus type 2. Pregnancy. No informed consent.

Design outcomes

Primary

Measure	Time frame
Number of MASLDs detected in patients with type 2 diabetes mellitus during the study period	—

Secondary

Measure	Time frame
Differentiation of the various MASLD diseases. Number of patients with early-detected HCC. Effectiveness of digital collaboration with specialized practices.	—

Countries

Germany

Contacts

Public ContactJörg Bojunga

Medizinische Klinik 1 der Universitätsmedizin Frankfurt

Joerg.Bojunga@unimedizin-ffm.de069 / 6301 - 5122

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026